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Enterobacter sakazakii kills 40%–80% of infected
infants and has been associated with powdered formula.
We analyzed 46 cases of invasive infant E. sakazakii infec-
tion to define risk factors and guide prevention and treat-
ment. Twelve infants had bacteremia, 33 had meningitis,
and 1 had a urinary tract infection. Compared with infants
with isolated bacteremia, infants with meningitis had
greater birthweight (2,454 g vs. 850 g, p = 0.002) and ges-
tational age (37 weeks vs. 27.8 weeks, p = 0.02), and infec-
tion developed at a younger age (6 days vs. 35 days,
p<0.001). Among meningitis patients, 11 (33%) had
seizures, 7 (21%) had brain abscess, and 14 (42%) died.
Twenty-four (92%) of 26 infants with feeding patterns spec-
ified were fed powdered formula. Formula samples associ-
ated with 15 (68%) of 22 cases yielded E. sakazakii; in 13
cases, clinical and formula strains were indistinguishable.
Further clarification of clinical risk factors and improved
powdered formula safety is needed.
E
nterobacter sakazakii, a gram-negative bacillus, is a
rare cause of bloodstream and central nervous system
infections (1–8). The organism has also been associated
with necrotizing enterocolitis; however, it has not been
firmly established as a causative agent (8–10). Reported
outcomes are often severe: seizures; brain abscess; hydro-
cephalus; developmental delay; and death in as many as
40%–80% of cases (11). Premature infants are thought to
be at greater risk than more mature infants, other children,
or adults, and outbreaks of disease have occurred in hospi-
tal units for newborns (1,2,4,6,8–10,12). Infant infections
with E. sakazakii have been associated with contaminated
powdered formula products, but other environmental
sources of contamination are possible (1,3,9,10,13). In this
analysis, we attempt to more clearly define the host risk
factors and disease course to refine prevention and treat-
ment efforts.
Methods
We reviewed the literature for reports of E. sakazakii
disease in infants. Using medical subject heading terms “E.
sakazakii” or “Enterobacter” in combination with “new-
born,” “infant,” or “meningitis,” we searched PubMed and
examined the bibliographies of resulting articles. Finally,
we reviewed E. sakazakii case consultations conducted by
the Centers for Disease Control and Prevention (CDC)
from 1998 to 2005 and reviewed results of a French out-
break reported to CDC in 2005 (14).
We defined a case as an infant (<12 months of age) with
E. sakazakii cultured from an area of the body that is nor-
mally sterile: tissue, blood, cerebrospinal fluid, or urine
aspirated through the bladder wall. Infants with cultures of
cerebrospinal fluid or brain abscesses yielding E. sakaza-
kii were considered to have meningitis. Because bac-
teremia is usually an intermediate step during the process
of developing meningitis, patients with both bacteremia
and meningitis were included in the meningitis group.
Bacteremia was defined as E. sakazakii grown from the
blood of a case-patient without evidence of meningitis.
Infants with gestational ages <37 weeks, or those
reported to be premature, were considered premature. A
gestational age of 40 weeks was assigned to 3 (27%) of 11
infants with bacteremia and 4 (14%) of 28 infants with
meningitis who were reported as born following term ges-
tation without a specific gestational age mentioned. We
defined birthweight <2,500 g as low birthweight (LBW),
<1,500 g as very low birthweight (VLBW), and <1,000 g
as extremely low birthweight (ELBW).
Descriptive analysis was performed by using SAS soft-
ware (SAS Institute, Cary, NC, USA). Groups were com-
pared by using 2-tailed Fisher exact test.
Results
Forty-six infants met the case definition (Table 1).
Reported onset years ranged from 1958 to 2005; 32 (70%)
cases were reported during the second half of this period.
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USACases were reported in 7 countries in North America,
Europe, and the Middle East. Thirty-three (72%) infants
had meningitis, 12 (26%) had bacteremia, and 1 (2%) had
a urinary tract infection.
Clinical characteristics were available for a subset of
cases (Table 2). Eight (40%) of 20 infants for whom data
were available were delivered by cesarean section.
Twenty-nine (69%) of 42 infants experienced disease onset
within a hospital. Gestational duration was available for 38
infants; 21 (55%) were born prematurely, and the median
gestational age overall was 36 weeks (range 23.5–40
weeks). The median birthweight was 2,063 g (range
540–3,401); 18 (56%) of 32 infants had LBW; 9 (28%) of
these met the definition for VLBW, and 7 (22%) met the
definition for ELBW. Median age at the time of infection
onset was 8.5 days (range 2–300).
Although the proportion of infants who experienced
nosocomial disease onset was not significantly different
between the meningitis and bacteremia groups, other
infant characteristics differed by site of infection (Figure).
The median gestational ages of infants with meningitis and
bacteremia were 37 and 27.8 weeks, respectively (p =
0.02). Median birthweights were 2,454 g and 850 g,
respectively (p = 0.002). However, median age at infection
onset was 6 days in the group with meningitis and 35 days
in the group with bacteremia (p < 0.0001). Thirty (94%) of
32 infants with meningitis, but only 2 (18%) of 11 infants
with bacteremia, were <28 days old when infection was
detected. One infant (8%) with bacteremia died; this infant
also had necrotizing enterocolitis. The single infant with a
urinary tract infection recovered without complication. In
contrast, 14 (42%) of 33 infants with meningitis died. Of
19 surviving infants, only those with meningitis suffered
adverse outcomes, including brain abscess (21%, p = 0.2),
developmental delays (53%, p = 0.004), motor impairment
(21%, p = 0.3), and ventricular shunt placement (42%, p =
0.01); 74% experienced at least one of these outcomes.
Feeding practices were described for 26 infants.
Twenty-four (92%) received a powdered formula product,
including an infant who received powdered breast milk
fortifier but no powdered infant formula; 1 additional
infant received formula of an unspecified type. E. sakaza-
kii was cultured from formula associated with 15 (68%) of
22 cases investigated. Isolates were obtained from pre-
pared formula, opened formula tins, and previously
unopened formula tins associated with 2, 6, and 7 cases,
respectively. Thirteen (87%) of the 15 formula isolates
were indistinguishable from the corresponding clinical
strain by biotype or genotype; multiple formula manufac-
turers were implicated. In one of the remaining cases, mul-
tiple E. sakazakii strains were recovered from powdered
formula, but none matched the clinical isolate by pulsed-
field gel electrophoresis (CDC, unpub. data). In the other
case, 2 E. sakazakii strains were isolated from blood and
from rectal swabs; a third strain, as determined by arbitrar-
ily primed PCR, was recovered from the powdered infant
formula (9).
Discussion
Although numerous reports include infants with E.
sakazakii isolated from nonsterile sites, such as respiratory
secretions or stool, 46 infants identified from the literature
and CDC sources met the case definition for this analysis
(1,9,10,12). Of the infants with sterile-site infection, 72%
had meningitis. Contrary to previous characterizations of
E. sakazakii disease, we found that infants with meningitis
and bacteremia alone fell into 2 distinct groups. Those in
whom meningitis developed tended to be of greater gesta-
tional age and birthweight than those with bacteremia
alone. In fact, infants in whom meningitis developed tend-
ed to attain near-term gestational age and birthweight. In
contrast, infants in whom bacteremia alone developed
tended to be born very prematurely and have ELBW. A
second major difference between the group with meningi-
tis and the group with bacteremia was the infants’chrono-
logical ages. Infants with meningitis were generally <1
week of age at the onset of infection with E. sakazakii,
whereas infants with bacteremia had generally surpassed
the neonatal period at the onset of their disease. Rates of
adverse outcome also differed between the 2 groups,
although this was not unexpected. Most infants with
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meningitis. Among those in whom meningitis developed,
rates of adverse outcome were similar to those reported in
the literature: In this case series, 74% of meningitis sur-
vivors experienced an adverse neurologic outcome, while
other studies cite adverse outcome in 20%–78% of neona-
tal or infant meningitis survivors (21–23).
The division of the infant population into 2 distinct
groups occurred for unclear reasons. That infants <1 week
of age comprised the meningitis group was not surprising;
the disparities in other infant characteristics, however, are
not intuitive. Since infants in the 2 groups experienced
similar rates of nosocomial disease onset, the infants with
bacteremia were unlikely to have simply received treat-
ment earlier in the disease course than the infants with
meningitis. Other risk factors are probable.
One likely set of risk factors is infant formula-feeding
practices. Powdered infant formula is a demonstrated
source of E. sakazakii infection. Amicrobiologic survey of
powdered infant formulas published in 1988 found E.
sakazakii in 20 (14%) of 141 samples tested (24).
However, a survey of 82 powdered infant formula samples
in 2003 yielded E. sakazakii in 2 (2.4%), which suggests
that recent rates of powdered formula contamination may
be lower (25). Powdered formula has also been implicated
both epidemiologically and microbiologically as a vehicle
in several cases of E. sakazakii disease in infants
(1,3,9,10,13). Although we could not explore feeding
exposures fully with the data available in this series, infant
feeding practices may relate to the differences we describe
in chronological age of infants at onset of meningitis and
bacteremia. Infants with nearly normal gestational ages
and birthweights are likely to be tended in normal newborn
nurseries during the first 24–72 hours of life. In such nurs-
eries, powdered formula is frequently given to babies who
are not breast-fed, and it may also be used as a supplement
by mothers who have chosen to breast-feed. Since infants
are at highest risk for meningitis during the first several
weeks of life, possibly because of immaturity of the blood-
brain barrier, exposures to E. sakazakii in powdered
formula or other sources during this time may quickly lead
to central nervous system disease (26,27). 
Conversely, in the intensive care settings where imma-
ture and low birthweight infants are tended, babies are not
often fed powdered formula in the first few weeks of life.
They may be given parenteral nutrition initially and may
be fed breast milk from their own mothers or from a
banked source when they do begin enteral feeds. If breast
milk is not available, they are more likely to be given ster-
ile, premixed infant formula than powdered formula, since
standard preterm infant formula is only available in this
form (28). Powdered breast milk fortifiers are not intro-
duced until premature infants tolerate full-volume feeds,
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Figure. Box plot with each box indicating range (vertical lines), first
and third quartiles (lower and upper boundaries of box, respective-
ly), and median value (horizontal solid line) for gestational age in
weeks, birth weight in grams, and age of onset in days for infants
with bacteremia only or meningitis. The dotted lines indicate medi-
an values for all cases. *Significantly different values (α=0.05)
between groups.which may not occur for days or weeks after birth. Thus,
infants in intensive care settings may not be exposed to
nonsterile formula until they are more mature, which
would lead to a greater proportion of E. sakazakii bac-
teremia than meningitis in this group if powdered formula
is a source of infection. In this series, we were unable to
explore the roles of indwelling enteric tubes, prior gas-
trointestinal surgery, and antecedent antacid or antimicro-
bial drug use as risk factors for infection.
While the reservoir for E. sakazakii is unknown, sever-
al environmental sources have been reported. E. sakazakii
has been isolated from factories used to produce milk pow-
der, chocolate, cereal, potato flour, spices, and pasta (29).
It also has been isolated from household vacuum cleaner
bags and from the guts of the stable fly, Stomoxys calci-
trans, and the Mexican fruit fly, Anastrpha ludens (29–31).
The relationship between these potential environmental
sources and infant disease remains unclear. Although a
human vaginal tract culture yielding E. sakazakii has been
reported, vertical transmission is unlikely because nearly
half of infants with E. sakazakii disease in this review were
delivered by cesarean section, and symptoms developed in
only 1 infant earlier than 3 days of age (32).
Our analyses were constrained by the use of retrospec-
tive and often incomplete data. Although cases with more
severe outcomes might have been investigated and pub-
lished more frequently than uncomplicated cases, this pos-
sible bias would not likely affect the representativeness of
baseline infant characteristics. Assigning a gestational age
of 40 weeks to term infants without a reported gestational
age may have falsely elevated the median gestational ages
we report, since most term infants are born at <40 weeks’
gestation (33). However, a greater proportion of bac-
teremic infants than meningitic infants received this
assignment, and therefore the significance of the differ-
ences in gestational age between the groups may be even
greater than we report. We were unable to explore the
effects of concomitant medical problems, treatments, and
other environmental factors, and we relied on existing
reports of feeding practices and formula testing. Clearly,
additional study is needed to elucidate the lingering ques-
tions about E. sakazakii reservoirs, disease risk factors,
and disease course.
Other gram-negative organisms, including Escherichia
coli, Enterobacter agglomerans, E. cloacae,  Klebsiella
pneumoniae, K. oxytoca, and Citrobacter freundii, can be
found in powdered infant formula (24,25). Powdered
infant formula also has been associated with outbreaks of
illness due to Citrobacter and multiple Salmonella
serotypes (13,34–38). The degree to which E. sakazakii is
a marker for a range of neonatal infections possibly relat-
ed to powdered infant formula remains to be defined.
Certain steps can be taken immediately, however, to
prevent or mitigate E. sakazakii disease. In a joint confer-
ence on infant formula safety in February, 2004, the World
Health Organization and Food and Agriculture
Organization of the United Nations made the following
recommendations: 1) encourage industry partners to devel-
op a range of affordable sterile formula options; 2) consid-
er setting an industry standard for Enterobacteriaecae and
E. sakazakii in infant formula; 3) inform infant caregivers
of the risks associated with nonsterile, powdered formula;
and 4) consider feeding high-risk infants sterile formula if
they cannot breast-feed (39). The findings of our case
review suggest that all neonates as well as premature
infants should be included in this high-risk infant catego-
ry. The American Dietetic Association has issued guide-
lines for infant formula preparation, storage, and
administration; these should be followed by infant care-
givers in hospitals and private homes (40). Rapid reporting
of cases by clinicians could streamline data collection by
local health departments and more rapidly resolve remain-
ing questions about this illness. Manufacturer warning
labels on powdered infant formula packages should stress
that powdered infant formula is nonsterile and requires
proper preparation, handling, and storage, and that sterile,
liquid formula alternatives are available. These actions,
adopted in whole or in part, may decrease the infectious
risks associated with powdered formula and prevent this
rare but potentially devastating disease.
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